All News

joint.pain_.hand_.PIP_.jpg

Are JAK Inhibitors Better at Pain Relief in RA?

d MedPage Today

Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.

Read Article
restless.legs.feet.spasm

Review of Restless Legs Syndrome

d Jack Cush, MD

JAMA has published a full read review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.

Read Article
emergency.jpg

Emergency Department Visits by Rheumatoid Patients

d Jack Cush, MD

A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population controls.

Read Article
Joint.pain.hands.blue

Smartphones and Rheumatoid Flares

d Jack Cush, MD

FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs. 

Read Article
This week’s RheumNow Live pre-Learn spotlight: Vasculitis & Autoimmune disease. We’re diving into this important topic with expert-led talks from Drs. Nancy Olsen, Matthew Baker, and Clay Cockerell. To help you get the most out of their sessions, our speakers have shared key https://t.co/zLKY52Fi17
Dr. John Cush RheumNow ( View Tweet)

Medicare Primary Care Shortage - betw 2013 -2021, PCPs decr 25%, while APPs rose 91%. 2021 AVAILABILITY per 10,000 Medicare beneficiaries; - Total clinicians: 23.4 to 22.2 (–5%) - Total new visits: 1162 to 1102 (–5%) - Total PCPs: 20.0 to 15.5 (–22%) - APPs: 3.4 to 6.7 (+97%) https://t.co/ALQI3O3Ian

Dr. John Cush RheumNow ( View Tweet)
Emergency Department Visits by Rheumatoid Patients A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population https://t.co/BL8AkXhkFG
Dr. John Cush RheumNow ( View Tweet)
Smartphones and Rheumatoid Flares FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs. https://t.co/xy6uqsQNt2 https://t.co/JwZlOLco6V

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?

Dr. John Cush RheumNow ( View Tweet)

What Is Restless Legs Syndrome? JAMA Patient Education handout. https://t.co/fCqArVxrSu https://t.co/xjl0PTdgsu

Links:

Dr. John Cush RheumNow ( View Tweet)
Nurse Practitioner Independence A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices. https://t.co/rkzLwhnNYh https://t.co/bxJWptPQK9

Links:

Dr. John Cush RheumNow ( View Tweet)

2024 Cardiology Income Survey - CV APP salary has incr 15% from 2019 -23, median=$123K - 50% of APP programs lead by an APP >90% work in outpt. clinics - 2/3 of prgs deploy APPs lipid & prevention management - 2 APPs for every 3 cardiologists https://t.co/gtdm5qN1qD https://t.co/cx2JUcw4U3

Links:

Dr. John Cush RheumNow ( View Tweet)
German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV

Links:

Dr. John Cush RheumNow ( View Tweet)
Evaluation of pts w/ muscle weakness and elevated muscle enzymes https://t.co/1Yn3OXXEH6 https://t.co/qsTr4U1xV7

Links:

Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd
Dr. John Cush RheumNow ( View Tweet)
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH

Links:

Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb
Dr. John Cush RheumNow ( View Tweet)
Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live is 3 weeks away, and we can't wait to see you there! Why Attend In Person? ✔ Engage directly with faculty during live Q&A ✔ Network with peers who influence and lead in rheumatology ✔ Experience the energy, pace, and collaboration that can’t be replicated https://t.co/Do8srChyXW
Dr. John Cush RheumNow ( View Tweet)
The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×